Sath Shukla Sells 17,641 Shares of Spero Therapeutics, Inc. (NASDAQ:SPRO) Stock

Spero Therapeutics, Inc. (NASDAQ:SPRO) CEO Sath Shukla sold 17,641 shares of Spero Therapeutics stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $1.31, for a total transaction of $23,109.71. Following the sale, the chief executive officer now owns 1,143,566 shares of the company’s stock, valued at approximately $1,498,071.46. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Sath Shukla also recently made the following trade(s):

• On Friday, August 2nd, Sath Shukla sold 14,800 shares of Spero Therapeutics stock. The shares were sold at an average price of $1.32, for a total transaction of $19,536.00.

Spero Therapeutics Price Performance

Shares of Spero Therapeutics stock traded down $0.07 during trading hours on Tuesday, hitting $1.27. The company’s stock had a trading volume of 323,154 shares, compared to its average volume of 222,742. The company has a market capitalization of $68.57 million, a PE ratio of 2.95 and a beta of 0.63. The stock has a 50 day moving average of $1.38 and a 200 day moving average of $1.51. Spero Therapeutics, Inc. has a 12 month low of $0.99 and a 12 month high of $1.89.

Spero Therapeutics (NASDAQ:SPRO) last posted its earnings results on Monday, August 5th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.01. Spero Therapeutics had a return on equity of 35.42% and a net margin of 21.09%. The business had revenue of $10.20 million during the quarter, compared to analysts’ expectations of $9.80 million. During the same period in the prior year, the business earned ($0.23) EPS. Equities analysts expect that Spero Therapeutics, Inc. will post -1.27 EPS for the current year.

Institutional Investors Weigh In On Spero Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. ADAR1 Capital Management LLC acquired a new stake in shares of Spero Therapeutics in the 4th quarter valued at about $1,570,000. Acadian Asset Management LLC grew its holdings in shares of Spero Therapeutics by 121.8% during the first quarter. Acadian Asset Management LLC now owns 762,598 shares of the company’s stock worth $1,310,000 after buying an additional 418,742 shares in the last quarter. Virtu Financial LLC acquired a new stake in Spero Therapeutics in the 1st quarter valued at approximately $31,000. Murchinson Ltd. raised its position in Spero Therapeutics by 1.3% in the 1st quarter. Murchinson Ltd. now owns 873,910 shares of the company’s stock valued at $1,503,000 after buying an additional 11,210 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in Spero Therapeutics by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 1,653,432 shares of the company’s stock valued at $2,844,000 after acquiring an additional 9,675 shares in the last quarter. 25.60% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms recently commented on SPRO. HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of Spero Therapeutics in a report on Tuesday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Spero Therapeutics in a research report on Tuesday. Finally, TD Cowen upgraded shares of Spero Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.